Search

everythinglearnresearchcommunity

for

Search:↓

CCCA is a common, scarring hair loss in Black women that needs early detection.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.

Researchers found a white halo around hair in most patients with a specific type of hair loss, which helps in early diagnosis and treatment.

Alopecia significantly lowers women's quality of life, with psychological and social challenges, highlighting the importance of early treatment and support.

Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.

Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.

Alopecia areata involves immune response and gene changes affecting hair loss.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

New biopsy techniques and tools improve alopecia diagnosis, and both too much and too little selenium can cause hair loss.

Cryotherapy may be an effective and simple treatment for mild hair loss with few side effects.

Thyroid disease can cause hair loss and treating thyroid problems might help with hair disorders.

Frontal Fibrosing Alopecia may be linked to autoimmune diseases like Sjögren's syndrome.

Alopecia areata is a reversible, autoimmune-related hair loss that can have significant emotional impact and uncertain treatment effectiveness.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Dilated follicular infundibula and increased catagen/telogen follicles are key indicators for diagnosing alopecia areata.

People with alopecia areata have a higher risk of stroke.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

The authors suggest that a new type of hair loss exists, which is different from alopecia areata.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

The conclusion is that it's important to tell apart alopecia areata from lipedematous alopecia for proper treatment, as alopecia areata can be reversed.

Lower vitamin D levels might be linked to more severe alopecia areata, but more research is needed to understand if vitamin D can help treat it.

Low vitamin D levels are linked to different types of hair loss.

The boy's hair loss was caused by the tuberculosis drug isoniazid but grew back after stopping the medication.